Wipro Ltd.

BSE: 507685 | NSE: WIPRO
Large Cap | IT - Software
175.35
2.60 (1.51%)
< Home < Back

Wipro partners with Transcell Oncologics to transform vaccine safety assessment strategies

Date: 06-05-2021

Wipro has entered into partnership with Transcell Oncologics to transform vaccine safety assessment using artificial intelligence. This alliance combines Transcell’s innovative stem cell technology with the advanced artificial intelligence capabilities of Wipro HOLMES, enabling customers to improve the safety of global vaccine immunization programs.

This alliance will add a new portfolio to Wipro HOLMES life sciences capability, which has impactful offerings that apply AI for drug repurposing and Messenger Ribonucleic Acid (mRNA) based platform for biodefense.

Wipro is a leading global information technology, consulting and business process services company.